Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Other Operating Expenses (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Other Operating Expenses data on record, last reported at $29.7 million in Q4 2025.

  • For Q4 2025, Other Operating Expenses fell 27.26% year-over-year to $29.7 million; the TTM value through Dec 2025 reached $102.2 million, down 13.16%, while the annual FY2025 figure was $102.2 million, 13.16% down from the prior year.
  • Other Operating Expenses reached $29.7 million in Q4 2025 per APLS's latest filing, up from $24.5 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $50.0 million in Q2 2021 and bottomed at $82000.0 in Q2 2022.
  • Average Other Operating Expenses over 5 years is $19.2 million, with a median of $20.2 million recorded in 2024.
  • Peak YoY movement for Other Operating Expenses: plummeted 99.84% in 2022, then soared 10118.29% in 2023.
  • A 5-year view of Other Operating Expenses shows it stood at $30.1 million in 2021, then plummeted by 90.27% to $2.9 million in 2022, then surged by 580.75% to $19.9 million in 2023, then skyrocketed by 105.18% to $40.9 million in 2024, then decreased by 27.26% to $29.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Operating Expenses were $29.7 million in Q4 2025, $24.5 million in Q3 2025, and $13.6 million in Q2 2025.